Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Not Applicable

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: PEG-rhG-CSF

First Posted Date: 2022-08-22

Last Posted Date: 2023-10-10

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 62

Registration Number: NCT05510089

Locations: 🇨🇳
Huzhou central hospital, Huzhou, Zhejiang, China
🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
The Affiliated People's Hospital of Ningbo University., Ningbo, Zhejiang, China

and more 9 locations

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Phase 2

Recruiting

Conditions: Group D Retinoblastoma
Bilateral Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma
Childhood Intraocular Retinoblastoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Etoposide
Procedure: Examination Under Anesthesia
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Procedure: Ultrasound Biomicroscopy
Drug: Vincristine

First Posted Date: 2022-08-17

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 26

Registration Number: NCT05504291

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Phase 4

Recruiting

Conditions: Hemophagocytic Lymphohistiocytoses
Cytokine Storm

Interventions: Drug: Ruxolitinib
Drug: Dexamethasone
Drug: Etoposide

First Posted Date: 2022-08-08

Last Posted Date: 2022-10-06

Lead Sponsor: The Children's Hospital of Zhejiang University School of Medicine

Target Recruit Count: 400

Registration Number: NCT05491304

Locations: 🇨🇳
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Phase 3

Recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell

Interventions: Drug: Chidamide
Drug: Carmustine
Drug: Cladribine
Drug: Etoposide
Drug: Gemcitabine
Drug: Cytarabine
Drug: Busulfan
Drug: Melphalan
Procedure: Autologous hematopoietic stem cell transplant

First Posted Date: 2022-07-20

Last Posted Date: 2022-07-25

Lead Sponsor: Sichuan University

Target Recruit Count: 306

Registration Number: NCT05466318

Locations: 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳
People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China

and more 8 locations

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Biological: Rituximab
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Lumbar Puncture
Procedure: Biospecimen Collection

First Posted Date: 2022-07-12

Last Posted Date: 2024-12-30

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT05453500

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer, Epithelial

Interventions: Drug: Envafolimab
Drug: Lenvatinib
Drug: VP-16

First Posted Date: 2022-06-16

Last Posted Date: 2022-06-16

Lead Sponsor: Zhongda Hospital

Target Recruit Count: 20

Registration Number: NCT05422183

Locations: 🇨🇳
Zhongda Hospital, Nanjing, Jiangsu, China

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1

Suspended

Conditions: Diffuse Large Cell Lymphoma
Non-Hodgkin Lymphoma
Burkitt Lymphoma
Plasmablastic Lymphoma
B-Cell Neoplasm

Interventions: Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin
Drug: Etoposide
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2022-05-25

Last Posted Date: 2024-11-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT05389423

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Lenvatinib
Drug: Pembrolizumab
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2022-05-20

Last Posted Date: 2024-02-20

Lead Sponsor: Fundación GECP

Target Recruit Count: 85

Registration Number: NCT05384015

Locations: 🇪🇸
Hospital General Universitario de Valencia, Valencia, Spain
🇪🇸
ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain

and more 15 locations

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Phase 1

Recruiting

Conditions: Wilms Tumor

Interventions: Drug: Vincristine
Drug: Irinotecan
Drug: Temozolomide
Drug: Etoposide
Drug: Cis-Retinoic acid

First Posted Date: 2022-05-20

Last Posted Date: 2023-10-16

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 28

Registration Number: NCT05384821

Locations: 🇫🇷
CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve, Montpellier, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHRU NANCY - Hôpital d'Enfants, Vandœuvre-lès-Nancy, France

and more 13 locations

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Phase 1

Recruiting

Conditions: B-cell Lymphoma
B-cell Acute Lymphoblastic Leukemia

Interventions: Drug: QN-019a
Drug: Rituximab
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: VP-16

First Posted Date: 2022-05-18

Last Posted Date: 2022-05-18

Lead Sponsor: Zhejiang University

Target Recruit Count: 24

Registration Number: NCT05379647

Locations: 🇨🇳
The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy